Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema. It also develops ARP-1536, a humanized monoclonal antibody that is in late stage preclinical development for the treatment of wet age-related macular degeneration; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a Phase 1a clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone513-985-1920
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Aerpio Pharmaceuticals (OTCMKTS:ARPO) Frequently Asked Questions
What is Aerpio Pharmaceuticals' stock symbol?
Aerpio Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ARPO."
How were Aerpio Pharmaceuticals' earnings last quarter?
Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) announced its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.18) by $0.03. View Aerpio Pharmaceuticals' Earnings History.
What price target have analysts set for ARPO?
5 equities research analysts have issued 1 year price targets for Aerpio Pharmaceuticals' shares. Their predictions range from $8.00 to $10.00. On average, they anticipate Aerpio Pharmaceuticals' stock price to reach $9.25 in the next twelve months. This suggests a possible upside of 840.8% from the stock's current price. View Analyst Price Targets for Aerpio Pharmaceuticals.
What is the consensus analysts' recommendation for Aerpio Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerpio Pharmaceuticals in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aerpio Pharmaceuticals.
What are Wall Street analysts saying about Aerpio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aerpio Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company' product candidates include AKB?9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals Inc. is based in Cincinnati, United States. " (4/9/2019)
- 2. HC Wainwright analysts commented, "As we roll forward the DCF analysis, our estimated market value of the firm has increased to $400M from $395M, which includes a discounted cash flow-based asset value for AKB-9778 and AKB-4924 (now GB004), using a 15% discount rate and 2% terminal growth rate, and probabilities of success at 30% and 10%, respectively." (3/6/2019)
Has Aerpio Pharmaceuticals been receiving favorable news coverage?
Media stories about ARPO stock have been trending positive this week, according to InfoTrie. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aerpio Pharmaceuticals earned a news sentiment score of 2.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the near term.
Are investors shorting Aerpio Pharmaceuticals?
Aerpio Pharmaceuticals saw a decrease in short interest in March. As of March 29th, there was short interest totalling 128,782 shares, a decrease of 79.4% from the March 15th total of 624,628 shares. Based on an average daily trading volume, of 1,888,024 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.5% of the company's shares are short sold. View Aerpio Pharmaceuticals' Current Options Chain.
Who are some of Aerpio Pharmaceuticals' key competitors?
Some companies that are related to Aerpio Pharmaceuticals include LifeVantage (LFVN), Tyme Technologies (TYME), Syndax Pharmaceuticals (SNDX), Aquestive Therapeutics (AQST), Ocular Therapeutix (OCUL), Humanigen (HGEN), BioXcel Therapeutics (BTAI), Northwest Biotherapeutics (NWBO), Chiasma (CHMA), CytoDyn (CYDY), AVEO Pharmaceuticals (AVEO), Trevena (TRVN), China SXT Pharmaceuticals (SXTC), Bellicum Pharmaceuticals (BLCM) and Axovant Sciences (AXON).
What other stocks do shareholders of Aerpio Pharmaceuticals own?
Who are Aerpio Pharmaceuticals' key executives?
Aerpio Pharmaceuticals' management team includes the folowing people:
- Dr. Joseph H. Gardner, Founder, Pres & Director (Age 62)
- Mr. Kevin G. Peters M.D., Ph.D., Chief Scientific Officer & Sr. VP (Age 61)
- Dr. Stephen Pakola M.D., Chief Medical Officer (Age 49)
- Dr. Stephen J. Hoffman, CEO & Director (Age 64)
- Mr. Michael W. Rogers, Chief Financial Officer (Age 58)
How do I buy shares of Aerpio Pharmaceuticals?
Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aerpio Pharmaceuticals' stock price today?
One share of ARPO stock can currently be purchased for approximately $0.9832.
How big of a company is Aerpio Pharmaceuticals?
Aerpio Pharmaceuticals has a market capitalization of $39.91 million.
What is Aerpio Pharmaceuticals' official website?
How can I contact Aerpio Pharmaceuticals?
Aerpio Pharmaceuticals' mailing address is 9987 CARVER ROAD, CINCINNATI OH, 45242. The company can be reached via phone at 513-985-1920 or via email at [email protected]
MarketBeat Community Rating for Aerpio Pharmaceuticals (OTCMKTS ARPO)
MarketBeat's community ratings are surveys of what our community members think about Aerpio Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
